Triple-negative breast cancer
Initial diagnosis: 2018 - 82 years old

“After thinking I was out of options, I'm now responding positively to targeted immunotherapy based on my Tumor Portrait™, proving that it's never too late for new beginnings.”
Nov, 2018
Initial diagnosis, biopsy
Stable Disease
Dec, 2018
Sep, 2022
First IHC (PD-L1 low expression)
Tumor Portrait™
Oct, 2022
BostonGene Tumor Portrait™ (PD-L1 high expression by RNA-seq)
Nov, 2022
Second IHC (subsequently confirmed a high expression PD-L1)
Good Response
Nov, 2022
Started immunotherapy in combination with chemotherapy
Complete Response
Feb, 2023
PET/CT scan

In 2018, Joan was diagnosed with triple-negative breast cancer at 82 and underwent a mastectomy. After the surgery, Joan's doctor ordered an immunohistochemistry (IHC) test. The test reported low levels of PD-L1, a critical marker for immunotherapy. Since these results indicated Joan was not a candidate for targeted PD-L1 immunotherapy, her doctor recommended chemotherapy, which Joan declined due to possible side effects. With limited treatment options, Joan's cancer progressed.

In 2022, she turned to BostonGene. The Tumor Portrait™ test uncovered high PD-L1 through comprehensive tumor profiling, a finding that was subsequently confirmed by a repeat PD-L1 IHC test. With these new test results, Joan was finally able to begin targeted PD-L1 immunotherapy.

To date, Joan has responded well to the new targeted treatment regimen. After only three months of her new immunotherapy regimen, Joan's PET/CT scans showed tumor shrinkage and fewer metastases.

To safeguard the privacy of our patients, we have altered the images in order to present real cases from their treatment journeys .